Finally, after months of foot-dragging, the Department of Health and Human Services’ Office of Inspector General has heeded our call for an investigation into the unprecedented and inappropriately close collaboration between Biogen and the FDA during the analysis of data from the key clinical trials of aducanumab (ADUHELM) for treatment of Alzheimer’s disease, which dangerously compromised the integrity of the FDA’s review of the drug.
Patients taking the commonly used stomach-acid–suppressing drugs lansoprazole (PREVACID, PREVACID 24 HR) and dexlansoprazole (DEXILANT) should be aware that these drugs have clinically important interactions with many other prescription medications.
A recent Government Account¬ability Office report found that direct-to-consumer prescription-drug advertising may be a major factor contributing to rising spending on medications by the Medicare program and its beneficiaries.
In this article, we discuss the results of a recent rigorously conducted study showing that therapy with the thyroid-hormone drug levothyroxine in older adults with subclinical hypo-thyroidism (a mild form of underactive thyroid) who had depressive symptoms provided no significant benefit.
Unfounded claims about the supportive roles of vitamin C and zinc for treating COVID-19 infection have led to increased demand and expenditures for these supplements, among others. Evidence from a recent study that was conducted by Cleveland Clinic researchers refutes these claims.
In his editor’s column, Dr. Michael Carome discusses why the FDA’s June approval of Biogen’s monoclonal-antibody drug aducanumab (ADUHELM) for the treatment of Alzheimer’s disease was one of the worst decisions in the agency’s history.
Patients taking the widely prescribed calcium channel blocker nifedipine (PROCARDIA, PROCARDIA XL) should be aware that it has clinically important interactions with many other prescription medications.